AstraZeneca's Farxiga Gets U.S. FDA Approval as Chronic-Kidney-Disease Treatment
By Anthony O. Goriainoff
AstraZeneca PLC said Tuesday that the U.S. Food and Drug
Administration approved Farxiga for the treatment of chronic kidney
disease in patients at risk of progression with, and without, Type
The London-listed pharmaceutical company said the sodium-glucose
cotransporter 2 inhibitor's approval was based on positive results
from the DAPA-CKD Phase III trial.
The company said Farxiga will be used to decrease the risk of
end-stage kidney disease, cardiovascular death, as well as
hospitalization for heart failure in adults with chronic kidney
disease at risk of progression, among others.
Write to Anthony O. Goriainoff at
(END) Dow Jones Newswires
May 04, 2021 02:33 ET (06:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.